Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase II results show safety and efficacy of VM-202 intramuscular injections in patients with CLI

April 3, 2014

Creabilis presents phase IIb data for CT-327 in psoriatic patients with chronic pruritus

April 3, 2014

Clinical data presented on sofosbuvir/ledipasvir fixed-dose combination for HCV

April 3, 2014

Array CGH-SNP analysis may identify undetected cases of myelodysplastic syndromes

April 2, 2014

Guselkumab is an effective, well-tolerated therapy for psoriasis according to phase II results

April 2, 2014

MicroRNAs may be biomarkers of drug-induced pancreatic injury

April 2, 2014

Clinical safety of abuse-deterrent analgesic formulations

April 2, 2014

Novel ultra-fast vaccine formulation shows safety and efficacy in phase IIb trial

April 2, 2014

New agents for dengue virus disclosed by SIGA Technologies

April 1, 2014

Bristol-Myers Squibb presents new agent for thrombosis

April 1, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...